title: A double- blind, randomized, and placebo-controlled clinical trial with omega-3 polyunsaturated fatty acids (OPFA ɷ-3) for the prevention of migraine in chronic migraine patients using amitriptyline.
abstract: OBJECTIVE
  To determine the prophylactic effect of OPFAϖ-3 in migraine.
  
  
  METHODS
  This was a prospective, experimental, controlled, double-blind, and with comparison groups study. Sixty patients diagnosed with chronic migraine, according to the criteria of the International Classification of Headache Disorders, Third Edition (beta version) (ICHD-3β), were prophylactically treated with amitriptyline. They were divided into two equal groups: in group 1, prophylaxis was associated with OPFAϖ-3 and in group 2 with placebo. After 60 days, both groups were assessed by a second researcher.
  
  
  RESULTS
  Of the 60 patients with chronic migraine, only 51 patients (15 men and 36 women) completed the treatment. The group that received OPFAϖ-3 consisted of 27 (52.9%) patients (six men and 21 women), while the control group was equal to 24 (47.1%) patients (nine men and 15 women). These differences were not significant (χ2= 1.428; P = 0.375). In 66.7% (18/27) of the patients who used OPFAϖ-3, there was a reduction of more than 80.0% per month in the number of days of headache, while in the control group, the same improvement occurred in 33.3% (8/24) of patients. This difference was significant (χ2= 5.649; P = 0.036).
  
  
  CONCLUSIONS
  Polyunsaturated omega 3 fatty acids (OPFAϖ-3) are useful for prophylaxis of migraine attacks.
authors.affiliation: a Center of Neurology and Headache of Piauí , Teresina , Brazil.
authors.forename: Adriana de Almeida
authors.initials: AA
authors.lastname: Soares
authors.affiliation: a Center of Neurology and Headache of Piauí , Teresina , Brazil.
authors.forename: Polyanna Mendes Camarço
authors.initials: PMC
authors.lastname: Louçana
authors.affiliation: b Botica Pharmacies , Teresina , Brazil.
authors.forename: Ema Pereira
authors.initials: EP
authors.lastname: Nasi
authors.affiliation: b Botica Pharmacies , Teresina , Brazil.
authors.forename: Kamila Maria de Holanda
authors.initials: KMH
authors.lastname: Sousa
authors.affiliation: c Santo Agostinho College , Teresina , Brazil.
authors.forename: Odara Maria de Sousa
authors.initials: OMS
authors.lastname: Sá
authors.affiliation: d Department of Neurology , Universidade Federal do Piauí , Teresina , Brazil.
authors.forename: Raimundo Pereira
authors.initials: RP
authors.lastname: Silva-Néto
mesh_terms: D000328:Adult; D000639:Amitriptyline / Q000009:adverse effects / Q000627:therapeutic use*; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000627:therapeutic use*; D001938:Brazil; D016009:Chi-Square Distribution; D059350:Chronic Pain / Q000209:etiology / Q000517:prevention & control*; D003131:Combined Modality Therapy; D019587:Dietary Supplements / Q000009:adverse effects; D004281:Docosahexaenoic Acids / Q000009:adverse effects / Q000627:therapeutic use; D004311:Double-Blind Method; D015118:Eicosapentaenoic Acid / Q000009:adverse effects / Q000627:therapeutic use; D015525:Fatty Acids, Omega-3 / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000178:diet therapy* / Q000188:drug therapy* / Q000503:physiopathology; D010147:Pain Measurement; D010352:Patient Dropouts; D012720:Severity of Illness Index
chemical_list: D018712:Analgesics, Non-Narcotic; D015525:Fatty Acids, Omega-3; D000639:Amitriptyline; D004281:Docosahexaenoic Acids; D015118:Eicosapentaenoic Acid
keywords: Fatty acids; Migraine; Omega 3; Prophylaxis